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A nationwide programme for the treatment of all
patients infected with hepatitis C virus (HCV) was
launched in Iceland in January 2016. By providing
universal access to direct-acting antiviral agents to
the entire patient population, the two key aims of
the project were to (i) offer a cure to patients and
thus reduce the long-term sequelae of chronic
hepatitis C, and (ii) to reduce domestic incidence
of HCV in the population by 80% prior to the WHO
goal of HCV elimination by the year 2030. An
important part of the programme is that vast
majority of cases will be treated within 36 months
from the launch of the project, during 2016–2018.
Emphasis is placed on early case finding and
treatment of patients at high risk for transmitting
HCV, that is people who inject drugs (PWID), as
well as patients with advanced liver disease. In
addition to treatment scale-up, the project also
entails intensification of harm reduction efforts,
improved access to diagnostic tests, as well as
educational campaigns to curtail spread, facilitate
early detection and improve linkage to care. With
these efforts, Iceland is anticipated to achieve the
WHO hepatitis C elimination goals well before
2030. This article describes the background and
organization of this project. Clinical trial number:
NCT02647879.
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hepatitis C, intravenous drug use, policy,
prevention.
Introduction
Hepatitis C virus (HCV) infection is one of the
leading causes of cirrhosis and hepatocellular
carcinoma (HCC) worldwide [1]. Injection drug
use (IDU) is the main mode of transmission in
developed countries, accounting for the majority of
new and existing infections [2]. In recent years, a
growing number of new direct-acting antiviral
(DAA) agents have become available, revolutioniz-
ing treatment for HCV. These new agents are highly
efficacious, have limited side effects and allow
shorter duration of treatment than previously
available medications [3]. However, treatment
uptake remains low in most countries, partly
because of high drug costs, particularly when they
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initially came on to the market, but also because of
barriers to care amongst people who inject drugs
(PWID). If treatment uptake remains low, DAAs are
likely to have minimal impact on reducing the
incidence and prevalence of HCV infection [4].
Much attention has been given recently to the
concept of treatment as prevention for HCV [5, 6].
Experience from HIV treatment shows that
antiretroviral therapy not only limits long-term
complications for those infected but also lowers
their likelihood of infecting others [7]. In contrast to
HIV, HCV is curable with relatively short course of
DAAs. Therefore, in the absence of an effective
vaccine against the virus, treatment as prevention
for HCV may provide an opportunity for preventing
onward transmission and reducing the prevalence
of the disease and its sequelae. Modelling work has
suggested that even by a modest scale-up of
treatment uptake amongst PWID, a significant
reduction in prevalence can be achieved [6]. Con-
sequently, HCV elimination using a treatment as
prevention approach combined with harm reduc-
tion efforts is considered attainable; WHO has set
elimination targets for hepatitis C, including a 65%
reduction in HCV-related deaths and 80% reduc-
tion in HCV incidence by 2030 [8]. Some countries
– including Georgia, Australia, Egypt, Portugal and
Spain – are also currently undertaking national
hepatitis C elimination efforts [9]. Iceland is an
ideal setting to examine the effectiveness of the
treatment as prevention approach in a real-world
setting. Results from recent mathematical mod-
elling for Iceland suggest that by intensifying harm
reduction, as well as diagnostic and treatment
efforts, the WHO targets for HCV elimination could
be achieved sooner than 2030, in fact even 6–
10 years earlier [10]. This study describes the
approach taken to achieve this goal.
Study setting and epidemiology of hepatitis C in Iceland
Iceland has a population of 340.000 – covered by
national health insurance [11]. It is a high-
income country with healthcare expenditure
amounting to 8.9% of GDP in 2014 [12, 13].
Iceland’s only university hospital (Landspitali
University Hospital, LUH), located in Reykjavik,
serves as a tertiary and quaternary referral centre
for the country and runs its only virology labo-
ratory. The majority of PWID seek services and
addiction treatment at Vogur Hospital, SAA –
National Center of Addiction Medicine (Society of
Alcoholism and other Addiction, SAA). Access to
treatment for addiction is good [14] reflected by
the fact that 7.5% of the living population in
Iceland over 14 years old have been admitted to
Vogur Hospital, SAA, for addiction treatment [15,
16]. SAA routinely screens all patients with
history of IDU for HCV. In Iceland, it is manda-
tory to report all HCV antibody diagnoses to the
Chief Epidemiologist. A registry of all diagnosed
cases of HCV has been kept since 1991.
Over the past 20 years, 40–70 new cases of HCV
have been diagnosed in Iceland every year (Fig. 1)
[17]. Assuming a viraemic rate of 80% amongst
antibody-positive individuals, the total HCV virae-
mic population in 2014 can be estimated to include
1100 (estimated range, 880–1300) individuals,
corresponding to a viraemic population prevalence
of 0.3% (0.3–0.4%) [18]. The vast majority of people
with HCV infection in Iceland have a history of IDU
[19].
The most commonly used drug amongst PWIDs in
Iceland has been the prescription drug methylphe-
nidate, which is indicated for the treatment of
attention deficit disorders [20, 21]. However,
majority of PWIDs treated at SAA use more than
one substance intravenously [22]. The prevalence
of HCV antibody amongst people who have ever
injected drugs is estimated at 45%, but amongst
people who have injected for a year or more, it is
almost 70% [22]. The most common HCV geno-
types are 3a (55%) and 1 (43%) [18].
Background of Trap Hep C in Iceland
The possibility of a nationwide HCV treatment/
elimination programmewas discussed in November
2014 by physicians managing HCV-infected
patients in Iceland and representatives of the
pharmaceutical company Gilead. The idea was to
offer DAAs to all HCV-positive patients within an
entire population within a relatively short time
frame and simultaneously initiate an observational
study with long-term follow-up. Gilead would, in a
study setting, provide DAAs free of charge for the
project. Upon approval of relevant parties in Iceland
(the Ministry of Health, Landspitali University
Hospital, Vogur Hospital – SAA and the Chief
Epidemiologist), formal preparation for a nation-
wide elimination programme was initiated, led by a
team of physicians at Landspitali University Hospi-
tal. Detailed clinical guidelines, a research protocol
and a practical project plan was drawn up, covering
staffing, equipment and other resources required.
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Another team was responsible for working with
Gilead Sciences Inc. to create a contractual agree-
ment for the project. Under this agreement, signed
in December 2015, Gilead provides DAAs in an
epidemiological study setting for a limited time
(36 months) for all HCV-positive individuals cov-
ered by the Icelandic health insurance system. The
Icelandic government provided special funding for
the overall organization of the project, diagnostic
tests and other services related to the nationwide
elimination campaign. The project was named
‘Treatment as Prevention for Hepatitis C in Iceland’
or ‘TraP HepC’ – to underline the fact that active
PWID, who are most likely to spread the virus,
would be the focus of the treatment effort.
TraP HepC research protocol
To measure the short-term and long-term effects of
TraP HepC, the incidence of HCV infection
acquired in Iceland and the incidence rates of
cirrhosis and HCC due to HCV will be monitored for
up to 15 years (Fig. 2). Additional factors, such as
virological response rates, compliance, and preva-
lence amongst PWID, are monitored as well. Use of
healthcare services and costs of treatment will be
tracked. These data as well as the data generated
during the project will be used to assess the effect
of the intervention on the future burden of illness
for patients and society. Informed consent is
obtained for each patient participating in the
study. Those who choose not to participate in the
research arm of the project are nevertheless offered
the same treatment and services. For consenting
subjects, study data will be extracted from elec-
tronic patient records. The initial (treatment) phase
of the research will be monitored by a clinical
research organization. The study is registered at
clinicaltrials.gov (trial number NCT02647879).
Main participating organizations and their roles
Landspitali University Hospital serves as a project
centre. The main collaborator of LUH is SAA. The
Chief Epidemiologist, on behalf of the Ministry of
Health, supervises the project. The project has a
general steering committee, as well as a research
steering committee.
Patient management and priority groups
The core of the treatment programme is based on
collaboration between two medical specialties at
LUH (infectious disease, hepatology) and the third,
addiction medicine, at SAA.
TraP HepC is based on a multidisciplinary team
approach, where physicians, nurses, psychosocial
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Fig. 1 Epidemiology of Hepatitis C in Iceland, 1991–2015. Yearly number of cases (left-hand y-axis) and annual incidence
per 100.000 inhabitants/year (right-hand y-axis), irrespective of the country of transmission. Graph based on data from the
Chief Epidemiologist, Directorate of Health, Iceland.
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support services (including shelters for the home-
less) and the penitentiary system in Iceland are all
involved. The initial evaluation and ongoing care
for the majority of patients take place in one of the
three main treatment sites, two at LUH and one at
SAA. In addition, evaluation and treatment are
provided by the TraP HepC staff members through
outreach in prisons, homeless shelters and other
locations as deemed necessary. Treatment is
offered to HCV-positive individuals who are cov-
ered by the Icelandic health insurance. All prison
inmates are offered HCV testing and subsequent
treatment if infection is confirmed. To reduce the
risk of re-infection, treatment is initiated simulta-
neously for all infected inmates in the initial
treatment phase. If released from the prison whilst
on treatment, prisoners are followed at one of the
TraP HepC treatment sites.
The overall aim was to treat the majority of HCV-
positive individuals within two years from the start
of the programme, using the third year to ‘mop-up’
any missed or incident cases (Fig. 2). Emphasis is
placed on early case finding and treatment for (i)
active PWID with HCV viremia, (ii) those at highest
risk for progression to cirrhosis or severe compli-
cations and (iii) inmates of the penitentiary system.
Patient recruitment
Using a dynamic compartmental model of HCV
transmission, it has been estimated that an 80%
reduction in domestic incidence is achievable in
Iceland by the years 2025 and 2020 if a minimum
of 75 of 1000 and 188 of 1000 PWID are treated per
year, respectively [10].
Patients are identified using cross-referencing of
four data sources: LUH’s virology laboratory sys-
tem, LUH’s administrative data sets (ICD diag-
noses), the hepatitis C registry and SAA’s database,
which contains comprehensive data on IDU and
virological test results for all patients admitted for
addiction treatment. Patients are contacted by
TraP Hep C staff members and informed of the
ongoing treatment programme and the therapeutic
options available and encouraged to visit one of the
three treatment sites. Patients living outside Reyk-
javik are offered travel bursary, and in some cases,
patients are evaluated and treatment initiated in
their hometown. Furthermore, to enhance clinical
awareness, letters of notice were sent to all physi-
cians in Iceland at the launch of the project and
regularly thereafter. In addition, in an effort to
reach out to those who may be at risk for infection
Fig. 2 Phases and timing of TraP HepC in Iceland. The active treatment phase (brown, orange and yellow columns) will last
36 months. Starting with initial case finding and treatment of patients with HCV infection which is already known, during
the first 24 months. Outreach will start after 12 months or earlier in select cases such as prisons. After the first 24 months
of active treatment, the focus will shift to new diagnosis and ‘mop-up’ of new cases of HCV in addition to remaining cases
identified by the Chief Epidemiologist. Relapses and reinfections will be treated during the entire 36-month period. The
endpoints for the first 36-month phase of the project include recruitment, completion of treatment, sustained virological
response (SVR), and prevalence in certain key populations. This part of the project will be monitored by a Clinical Research
Organisation (CRO). Monitoring of long-term effects of the TraP HepC project (red column) will ensue immediately following
the active treatment phase; here, the incidence of domestic transmission will be monitored as well as long-term
complications from chronic HCV infection for up to 15 years. It is important to note that the different components of TraP
HepC may overlap.
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but have not been diagnosed information has been
made available to patients through media outlets
such as web pages, social media and information
leaflets, which are sent to every home in the
country. Patients can contact the programme via
e-mail and a toll-free number to register for coun-
selling, testing and treatment.
Rapid testing is offered in select sites, including
shelters.
Evaluation, treatment and monitoring
It has been estimated that byoffering treatment toup
to 200 patients every 4 months, the majority will be
treated within the first two years of the programme
(Fig. 2). Interview, laboratory work (including viro-
logical tests) and hepatic elastography (Fibroscan)
are generally undertaken at the baseline visit. A
mobile Fibroscan is available for incarcerated
patients and others unable to visit the treatment
centres. Qualifying patients start treatment accord-
ing to the guidelines within four weeks and prefer-
ably within two weeks of their initial workup.
Patients are interviewed by a physician at the initial
(baseline) and final visits (following HCV PCR testing
at 12 weeks posttherapy). Most other interviews are
conducted by nurses. In the programme, DAAs are
prescribed by specialists in addiction medicine,
hepatology and infectious disease.
Electronic patient record subsystem – remote access
Patient data are entered at the point of care directly
into an electronic patient record (EPR) using a
customized interactive module. Data are recorded
and stored in the EPR using the patient’s personal
ID number. This module of the EPR is designed to
support structured data entry (most data are
entered in numerical or coded format). A list of
the personal ID numbers of those participating in
the research project will be used to extract study
data from the EPR for inclusion in a separate de-
identified study database.
Treatment regimens
During the initial phase (from January to October
2016), all patients were treated with ledipasvir/
sofosbuvir (Harvoni), in most cases for 8–
12 weeks, with patients with genotype 3 also
receiving ribavirin (Table 1). From November
2016, all patients have been treated with sofosbu-
vir/velpatasvir (Epclusa, Table 2). Patients who
have a contraindication for these agents have
access to other treatment regimens.
Approach to PWID
Methods to optimize adherence include on-treat-
ment monitoring, pill boxes, increased nurse coun-
selling and support, linkage to other relevant
health services (e.g. addiction treatment, psychi-
atric services), travel stipends for those living
outside Reykjavik and incentives, such as prepaid
mobile phone cards. Harm reduction education
and counselling are provided in the context of
treatment. PWID are encouraged to bring their
friends and injection partners for testing and
treatment with the aim of treating injecting
partners simultaneously to decrease the risk of
re-infection [23].
Table 1 Most common initial treatment regimens for chronic HCV in Iceland, from January to October 2016, according to the
Icelandic treatment guidelines
GT 1,4,5,6
TN, noncirrhotic LDV/SOF Viral load <6 million IU/mL, 8 weeks (GT 1 only)
TN, noncirrhotic LDV/SOF Viral load >6 million IU/mL, or non-GT-1, 12 weeks
TN, cirrhotic LDV/SOF 12 weeks
TE, noncirrhotic LDV/SOF 12 weeks
TE, cirrhotic LDV/SOF+RBV 12 weeks (24 weeks if no RBV)
Decompensated/post-transpl LDV/SOF+RBV 12 weeks (24 weeks if no RBV)
GT 3
TE or cirrhosis LDV/SOF+RBV 24 weeks (24 weeks if no RBV)
TN LDV/SOF+RBV 12 weeks (24 weeks if no RBV)
IU, international units; GT, genotype; TN, treatment-na€ıve; TE, treatment-experienced; LDV, ledipasvir; SOF, sofosbuvir;
RBV, ribavirin; HCV, hepatitis C virus.
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Harm reduction
A formal collaboration has been established with
The Icelandic Red Cross, which runs a mobile
harm reduction unit, providing a needle-syringe-
programme (NSP) in the capital city, Reykjavik.
Furthermore, collaboration has been established
with pharmacies where needles and syringes can
be obtained at a very low cost to lower barriers for
PWID. The estimated annual number of clean
needles and syringes provided to each injection
drug user in Iceland is 430.
Sterile injecting instruments and prepackaged
‘kits’ are offered to PWID seeking services at LUH
and SAA. There is also interest in providing NSP
within the penitentiary system and this is under
consideration. In Iceland, PWIDs with opiate addic-
tion have had access to opioid substitution treat-
ment (OST) since 1999, most commonly
buprenorphine/naloxone (Suboxone). Currently,
a total of 120 patients are receiving OST treatment,
run by SAA – the National Center of Addiction
Medicine. However, the absence of pharmacologi-
cal substitute treatment for stimulant users, which
comprise the majority of active PWID in Iceland,
remains a challenge.
Intensified screening efforts
An important component of TraP HepC is an
intensified screening of risk groups. The use of
point-of-care testing (rapid tests) for HCV and HIV
is applied to approach patient populations that are
difficult to reach, such as those visiting homeless
shelters, halfway houses and the mobile harm
reduction unit. Screening has been increased at
emergency rooms, addiction treatment centres,
within the penitentiary system and at other rele-
vant locations. Public awareness campaigns in the
mass media focus on people at risk who have not
yet sought testing.
Monitoring of re-infections
As successful antiviral therapy does not confer
subsequent immunity to HCV, re-exposure to the
virus can lead to re-infection. Screening and repeat
referral will continue for all risk groups (including
PWID) at the time of healthcare contact, for exam-
ple when they seek care in emergency rooms or
when admitted to addiction treatment centres.
Practicing clinicians are encouraged to order HCV
and HIV tests amongst PWID if prior tests were
taken more than 6 months ago. The incidence of
re-infections will also be monitored by offering all
patients previously treated and cured to have their
HCV RNA measured 12 months post-treatment.
Initial treatment results
In the real-world setting of Iceland fifteen months
after launching the TraP HepC, 557 individuals
have been evaluated (68% males, 32% females),
comprising 56–70% of the estimated total number
of viraemic patients. Thereof, treatment has been
initiated for 526 patients, 363 LDV/SOF-based,
162 SOF/VEL-based and 1 other regimen. The
mean age is 42 years and at the time of baseline
evaluation 37% of the patients reported IDU in the
past 6 months. Virological response rates are gen-
erally high; however, individuals who are homeless
were less likely to achieve sustained virological
response (SVR) at 12 weeks (74% compared to
94%, P = 0.0005) and those who report current
IDU are also significantly less likely to achieve SVR
at 12 weeks (87% compared to 95%, P = 0.003)
[24]. No serious adverse events have been reported.
Pitfalls and challenges
There are several potential challenges facing the
TraP HepC initiative. Visitors from abroad, such as
tourists, temporary workers, immigrants, incarcer-
ated and asylum seekers, with pre-existing chronic
Table 2 Most common initial treatment regimens for chronic HCV in Iceland, from November 2016 onwards, according to the
Icelandic treatment guidelines
GT 1,2,3,4,5,6
TN, TE, cirrhotic, noncirrhotic SOF/VEL 12 weeks
Decompensated cirrhosis SOF/VEL+RBV 12 weeks (24 weeks if no RBV)
GT, genotype; TN, treatment-na€ıve; TE, treatment-experienced; VEL, velpatasvir; SOF, sofosbuvir; RBV, ribavirin; HCV,
hepatitis C virus.
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HCV infections, may facilitate or maintain trans-
mission of the virus during their visit to Iceland.
For example, there are HIV transmission clusters
in Iceland, which are known to have originated in
Eastern Europe [25]. In addition, the number of
workers from foreign countries as well as tourists
has increased dramatically in Iceland over the past
five years [26, 27]. Coinciding with this, the police
authorities have expressed their concern for an
increase in the sex trade [28, 29]. It is also known
that unprotected sexual activity amongst men who
have sex with men (MSM) in Europe is on the rise,
which goes hand in hand with increased incidence
of sexually transmitted infections, including HIV,
syphilis and HCV [30–32]. It should be noted,
however, that all immigrants and asylum seekers
from outside the European Union are screened for
HCV in Iceland within weeks from arrival and those
who immigrate are offered treatment as part of
their health insurance coverage. International
travel, most likely, is uncommon amongst active
PWID, due to limited financial means. However,
travel amongst Icelandic MSM for the purpose of
sex may be quite common although limited data
exist on this [33].
The long-term continued access to DAA’s, screen-
ing for HCV and harm reduction programmes, will
be dependent on continued political support once
the current financial support by the Ministry of
Health and provision of DAA’s by Gilead comes to
an end. Successful elimination of the disease might
reduce the sense of urgency and vigilance towards
protection, detection and treatment of hepatitis C
amongst those at risk. On the other hand, suc-
cessful elimination based on the treatment
approach of this project might strengthen political
support for maintaining high access to both DAA’s
and effective screening for HCV as well as other
resources needed for prevention, harm reduction
and treatment.
Summary and conclusions
In summary, with the TraP Hep C programme,
Iceland is taking a cohesive, multipronged
approach that includes scale-up of prevention,
testing and early treatment of hepatitis C in both
hospital and community settings. It includes a
multidisciplinary public health model of care and
cooperation between government, health services,
the penitentiary system and community organiza-
tions. Although some parts of this programme are
empirical in nature and highly dependent on
intangibles, such as vigilance and motivation
amongst healthcare professionals and the public
alike, it is hoped that treatment as prevention will
lower the incidence and morbidity associated with
HCV well in advance of the WHO targets. The
results of Icelandic project will provide important
data and inform others globally trying to achieve
the WHO hepatitis C elimination goals.
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